Berenberg Bank Reiterates “Buy” Rating for Genus (LON:GNS)

Genus (LON:GNSGet Free Report)‘s stock had its “buy” rating restated by equities research analysts at Berenberg Bank in a research note issued on Tuesday,London Stock Exchange reports. They currently have a GBX 3,350 target price on the stock. Berenberg Bank’s price target would indicate a potential upside of 58.17% from the stock’s current price.

Genus Stock Up 4.1%

Shares of GNS opened at GBX 2,118 on Tuesday. Genus has a 52 week low of GBX 1,943 and a 52 week high of GBX 3,220. The stock has a market capitalization of £1.41 billion, a price-to-earnings ratio of 29.83, a PEG ratio of 2.87 and a beta of 0.90. The company has a debt-to-equity ratio of 51.73, a quick ratio of 1.08 and a current ratio of 2.25. The stock has a fifty day moving average of GBX 2,246.45 and a 200-day moving average of GBX 2,553.64.

Insider Buying and Selling

In other news, insider Jorgen Kokke sold 3,450 shares of the firm’s stock in a transaction on Wednesday, May 13th. The shares were sold at an average price of GBX 2,267, for a total transaction of £78,211.50. Also, insider Celia Baxter acquired 2,336 shares of Genus stock in a transaction that occurred on Friday, June 26th. The stock was acquired at an average cost of GBX 2,140 per share, for a total transaction of £49,990.40. Insiders own 0.71% of the company’s stock.

Genus Company Profile

(Get Free Report)

Genus plc operates as an animal genetics company in North America, Latin America, the United Kingdom, rest of Europe, the Middle East, Russia, Africa, and Asia. The company operates through three segments: Genus PIC, Genus ABS, and Genus Research and Development. It sells breeding pigs and semen to breed pigs with various characteristics for pork production under the PIC brand. The company also sells bull semen and embryos to breed calves with various characteristics for milk and beef production under the ABS, Genus, and Bovec brands.

Read More

Receive News & Ratings for Genus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genus and related companies with MarketBeat.com's FREE daily email newsletter.